Performance of the 2010 ACR/EULAR criteria for rheumatoid arthritis: comparison with 1987 ACR criteria in a very early synovitis cohort

被引:125
作者
Cader, Mohammed Z. [2 ]
Filer, Andrew [1 ,2 ]
Hazlehurst, Jonathan [2 ]
de Pablo, Paola [1 ,2 ]
Buckley, Christopher D. [1 ,2 ]
Raza, Karim [1 ,2 ]
机构
[1] Univ Birmingham, Coll Med & Dent Sci, Sch Immun & Infect, Rheumatol Res Grp, Birmingham B15 2TT, W Midlands, England
[2] Sandwell & W Birmingham Hosp NHS Trust, Dept Rheumatol, Birmingham, W Midlands, England
关键词
LONG-TERM IMPACT; RHEUMATOLOGY/EUROPEAN LEAGUE; CLASSIFICATION CRITERIA; AMERICAN-COLLEGE; PREDICTION RULE; BENEFIT;
D O I
10.1136/ard.2010.143560
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Early identification of patients with rheumatoid arthritis (RA) is essential to allow the prompt institution of therapy. The 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria, which replace the 1987 classification criteria, have been developed to facilitate such identification in patients with newly presenting inflammatory arthritis. This study therefore assesses the performance of these new criteria in patients with early synovitis. Methods Data were analysed from patients with synovitis seen within 3 months of the onset of inflammatory arthritis. Patients were followed for 18 months to determine outcomes, and data on the cumulative fulfilment of 2010 and 1987 criteria and therapy were recorded. Results 265 patients were included in the study. 60 had alternative diagnoses at baseline. Of the remaining 205 patients, 20% fulfilled both 1987 and 2010 criteria, 3% fulfilled only 1987 criteria and 22% fulfilled only 2010 criteria at baseline. The 2010 criteria, when applied at baseline, detected more patients who eventually required disease-modifying antirheumatic drugs (DMARD) (65 (62%) vs 40 (38%); p<0.001), especially methotrexate (50 (68%) vs 31 (42%); p<0.01), within the first 18 months. However, more patients whose disease eventually resolved without ever requiring DMARD were classified at baseline as RA according to the 2010 criteria than with the 1987 criteria (16 (8%) vs 5 (2%); p=0.01). Conclusion The 2010 ACR/EULAR criteria allow more rapid identification of patients requiring methotrexate compared with the 1987 ACR criteria when applied at baseline. However, overdiagnosis is an important issue to consider if these criteria are to be used in very early disease.
引用
收藏
页码:949 / 955
页数:7
相关论文
共 14 条
[1]  
Aletaha D, 2010, ANN RHEUM DIS, V69, P1580, DOI [10.1136/ard.2010.138461, 10.1002/art.27584]
[2]   THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].
ARNETT, FC ;
EDWORTHY, SM ;
BLOCH, DA ;
MCSHANE, DJ ;
FRIES, JF ;
COOPER, NS ;
HEALEY, LA ;
KAPLAN, SR ;
LIANG, MH ;
LUTHRA, HS ;
MEDSGER, TA ;
MITCHELL, DM ;
NEUSTADT, DH ;
PINALS, RS ;
SCHALLER, JG ;
SHARP, JT ;
WILDER, RL ;
HUNDER, GG .
ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324
[3]   Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis [J].
Finckh, Axel ;
Liang, Matthew H. ;
van Herckenrode, Carmen Mugica ;
de Pablo, Paola .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2006, 55 (06) :864-872
[4]   The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Methodological Report Phase I [J].
Funovits, Julia ;
Aletaha, Daniel ;
Bykerk, Vivian ;
Combe, Bernard ;
Dougados, Maxime ;
Emery, Paul ;
Felson, David ;
Hawker, Gillian ;
Hazes, Joanna M. ;
Huizinga, Tom ;
Kay, Jonathan ;
Kvien, Tore K. ;
Smolen, Josef S. ;
Symmons, Deborah ;
Tak, Paul P. ;
Silman, Alan .
ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (09) :1589-1595
[5]  
Green M, 1999, ARTHRITIS RHEUM, V42, P2184, DOI 10.1002/1529-0131(199910)42:10<2184::AID-ANR20>3.0.CO
[6]  
2-2
[7]   Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis [J].
Nell, VPK ;
Machold, KP ;
Eberl, G ;
Stamm, TA ;
Uffmann, M ;
Smolen, JS .
RHEUMATOLOGY, 2004, 43 (07) :906-914
[8]   The 2010 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Rheumatoid Arthritis Phase 2 Methodological Report [J].
Neogi, Tuhina ;
Aletaha, Daniel ;
Silman, Alan J. ;
Naden, Raymond L. ;
Felson, David T. ;
Aggarwal, Rohit ;
Bingham, Clifton O., III ;
Birnbaum, Neal S. ;
Burmester, Gerd R. ;
Bykerk, Vivian P. ;
Cohen, Marc D. ;
Combe, Bernard ;
Costenbader, Karen H. ;
Dougados, Maxime ;
Emery, Paul ;
Ferraccioli, Gianfranco ;
Hazes, Johanna M. W. ;
Hobbs, Kathryn ;
Huizinga, Tom W. J. ;
Kavanaugh, Arthur ;
Kay, Jonathan ;
Khanna, Dinesh ;
Kvien, Tore K. ;
Laing, Timothy ;
Liao, Katherine ;
Mease, Philip ;
Menard, Henri A. ;
Moreland, Larry W. ;
Nair, Raj ;
Pincus, Theodore ;
Ringold, Sarah ;
Smolen, Josef S. ;
Stanislawska-Biernat, Ewa ;
Symmons, Deborah ;
Tak, Paul P. ;
Upchurch, Katherine S. ;
Vencovsky, Jiri ;
Wolfe, Frederick ;
Hawker, Gillian .
ARTHRITIS AND RHEUMATISM, 2010, 62 (09) :2582-2591
[9]   Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal - Results from a twelve-month randomized, double-blind, placebo-controlled trial [J].
Quinn, MA ;
Conaghan, PG ;
O'Connor, PJ ;
Karim, Z ;
Greenstein, A ;
Brown, A ;
Brown, C ;
Fraser, A ;
Jarret, S ;
Emery, P .
ARTHRITIS AND RHEUMATISM, 2005, 52 (01) :27-35
[10]   The Michael Mason prize: early rheumatoid arthritis-the window narrows [J].
Raza, Karim .
RHEUMATOLOGY, 2010, 49 (03) :406-410